We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Ground-Breaking Tool Predicts 10-Year Risk of Esophageal Cancer

By HospiMedica International staff writers
Posted on 17 Aug 2023

Esophageal cancer, which affects the long tube that carries food from the throat to the stomach, ranks as the 8th most prevalent cancer globally and is a major health concern. More...

Since it often goes undetected until advanced stages, early identification is vital. Though detection methods like endoscopy exist, they are typically used for symptomatic patients or those known to be at high risk. Now, a ground-breaking tool could revolutionize the early detection of esophageal cancer by predicting an individual’s risk of getting the disease over the next 10 years.

Researchers at Oxford University (Oxford, UK) have developed an innovative tool called CanPredict (esophageal) to predict the 10-year risk of esophageal cancer. The tool can also identify high-risk patients for further screening, enabling earlier detection and improved patient outcomes. The development of CanPredict involved analyzing the anonymized medical records of over 12 million patients and over 16,000 esophageal cancer cases from the QResearch database across England. Factors such as age, lifestyle habits, medical history, and medication use were incorporated into the CanPredict algorithm using cutting-edge computational techniques. CanPredict's accuracy was evaluated by testing it with over four million patients from a separate set of QResearch practices and over 2.5 million patients from the Clinical Practice Research Database. The tests showed that CanPredict could accurately predict an individual's risk of esophageal cancer within the following ten years, and it performed better than existing risk estimation models.

Utilizing CanPredict to focus on only the top 20% of high-risk individuals could lead to the detection of more than three-quarters (76%) of probable esophageal cancer cases in the next decade. Notably, the research underscored the significance of elements such as age, body mass index, smoking, alcohol intake, and prior medical conditions in assessing the likelihood of developing esophageal cancer. CanPredict's ability to integrate these factors into its evaluation results in a comprehensive and personalized risk assessment. The newly-developed tool offers potential not just for improving patient care through early detection but also for optimizing medical resources by targeting those facing the highest risk who stand to benefit the most from screening.

“CanPredict offers a tailored approach, concentrating on those most in need, and identifying patients at risk of esophageal cancer,” said Professor Julia Hippisley-Cox, lead researcher at the University of Oxford. “This has the potential to make diagnoses of cancer earlier when there are likely to be more treatment options.”

“Our study bridges a significant gap in primary care,” added Winnie Mei, co-author and Research Fellow at the University of Oxford. “By identifying high-risk patients earlier, we can potentially offer them life-saving interventions. This tool is a testament to the power of combining technology with medical research.”

Related Links:
Oxford University 


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.